EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

BH3 mimetics and TKI combined therapy for Chronic Myeloid Leukemia

Gabriela Brumatti, Deeksha Kaloni, Fabíola Attié Castro, Gustavo P Amarante-Mendes iD

Biochemical Journal · 2023

DOI: 10.1042/bcj20210608 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biochemical Journal, 2023. Verfasst von Gabriela Brumatti und 3 weiteren Autor:innen. Beteiligte Einrichtung: Inflammation Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Protein Kinase Inhibitors. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 144 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic myeloid leukemia (CML) was considered for a long time one of the most hostile leukemia that was incurable for most of the patients, predominantly due to the extreme resistance to chemotherapy. Part of the resistance to cell death (apoptosis) is the result of increased levels of anti-apoptotic and decreased levels of pro-apoptotic member of the BCL-2 family induced by the BCR-ABL1 oncoprotein. BCR-ABL1 is a constitutively active tyrosine kinase responsible for initiating multiple and oncogenic signaling pathways. With the development of specific BCR-ABL1 tyrosine kinase inhibitors (TKIs) CML became a much more tractable disease. Nevertheless, TKIs do not cure CML patients and a substantial number of them develop intolerance or become resistant to the treatment. Therefore, novel anti-cancer strategies must be developed to treat CML patients independently or in combination with TKIs. Here, we will discuss the mechanisms of BCR-ABL1-dependent and -independent resistance to TKIs and the use of BH3-mimetics as a potential tool to fight CML.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug Resistance, NeoplasmLeukemia, Myelogenous, Chronic, BCR-ABL PositiveProtein Kinase InhibitorsHumansFusion Proteins, bcr-ablSignal Transduction

Stichwörter der Autor:innen

BCR-ABL1BH3-mimeticschronic myeloid leukemiatyrosine kinase inhibitors

Substanzen

Fusion Proteins, bcr-ablProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Inflammation Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.
  • Department of Medical Biology, University of Melbourne, Melbourne, VIC, Australia.
  • Blood Cells and Blood Cancer Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.
  • Departamento de Análises Clínicas, Toxicológicas e Bromatológicas, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brazil.
  • Departamento de Imunologia, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, Brazil.
  • Instituto de Investigação em Imunologia, Instituto Nacional de Ciência e Tecnologia (INCT-iii), São Paulo, Brazil.

ORCID-Profile: Gustavo P Amarante-Mendes

Zitieren

APA

Brumatti, G., Kaloni, D., Castro, F. A., & Amarante-Mendes, G. P. (2023). BH3 mimetics and TKI combined therapy for Chronic Myeloid Leukemia. Biochemical Journal. https://doi.org/10.1042/bcj20210608

Vancouver

Brumatti G, Kaloni D, Castro FA, Amarante-Mendes GP. BH3 mimetics and TKI combined therapy for Chronic Myeloid Leukemia. Biochemical Journal. 2023. doi:10.1042/bcj20210608

BibTeX
@article{Brumatti2023,
  author = {Brumatti, Gabriela and Kaloni, Deeksha and Castro, Fabíola Attié and Amarante-Mendes, Gustavo P},
  title = {BH3 mimetics and TKI combined therapy for Chronic Myeloid Leukemia},
  journal = {Biochemical Journal},
  year = {2023},
  doi = {10.1042/bcj20210608}
}
Kostenlos starten →